Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women after Assisted Reproductive Technology (APPART)
2022-500933-10-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in preeclampsia comparing Aspirin arm with Placebo arm (2 arms). Primary endpoint: Preterm preeclampsia (<37 weeks). Planned start Oct 2022; status: authorised.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2022-500933-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500933-10-00.